CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: October 11, 2016
Result type: Reports
Project Number: SR0506-000
Product Line: Reimbursement Review

Generic Name: Ivabradine

Brand Name: Lancora

Manufacturer: Servier Canada Inc.

Therapeutic Area: Heart failure, NYHA class II or III

Indications: Heart failure, NYHA class II or III

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: May 24, 2017

Recommendation Type: Reimburse with clinical criteria and/or conditions